Drug Shows Positive Responses, Low Side Effects in Multiple Myeloma

The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported Monday at the 51st Annual Meeting of the American Society of Hematology.
PhysOrg